Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.07. | Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds | 1 | Investing.com | ||
16.07. | Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest | 1 | Investing.com Deutsch | ||
16.07. | Orexo AB: Orexo Q2 2025 Interim Report | 79 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
02.06. | Orexo to present clinical data for OX640 at the EAACI Congress | 212 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
OREXO Aktie jetzt für 0€ handeln | |||||
06.05. | Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements | 1 | Investing.com | ||
06.05. | Orexo AB: Orexo Q1 2025 Interim Report | 110 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
10.04. | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 341 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 121 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 434 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 467 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 331 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 335 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
24.10.24 | Orexo Interim Report Q3 2024 | 478 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
04.10.24 | Orexo's Nomination Committee for the Annual General Meeting 2025 | 340 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen | |
03.09.24 | Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024 | 330 | PR Newswire | UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 4,115 | +0,12 % | Northern Lights Forecast: Aurora Borealis Potentially Viewable From 8 States Tonight | ||
ABBVIE | 162,20 | 0,00 % | UK MHRA green lights AbbVie's ELAHERE for ovarian cancer | ||
TILRAY BRANDS | 0,570 | -2,63 % | Tilray Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
BRISTOL-MYERS SQUIBB | 41,580 | +0,80 % | Bristol Myers Squibb beruft neuen Chief Medical Officer | Der US-Pharmakonzern Bristol Myers Squibb hat am Freitag bekanntgegeben, dass Cristian Massacesi zum 1. August 2025 die Rolle des Executive Vice President, Chief Medical Officer und Leiters der weltweiten... ► Artikel lesen | |
TEVA | 14,050 | -0,35 % | Israeli institutional investors bet on Teva | ||
VERTEX PHARMACEUTICALS | 403,15 | +0,81 % | Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis | ||
EYEPOINT PHARMACEUTICALS | 8,586 | -3,74 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
BAUSCH HEALTH | 5,733 | -0,62 % | Bausch Health Companies Inc.: Bausch Health Announces the Appointment of Two New Members to Its Board of Directors | LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 68,49 | +0,56 % | Edwards Lifesciences Corp. Reports Retreat In Q2 Income | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) reported earnings for second quarter that Drops, from the same period last yearThe company's bottom line totaled $333.2 million, or $0.56... ► Artikel lesen | |
BIONANO GENOMICS | 3,390 | -3,00 % | Bionano Genomics: Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 5,550 | -2,63 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
AMARIN | 12,900 | -1,53 % | Amarin Gears Up to Report Q2 Earnings: Here's What to Expect | ||
OPKO HEALTH | 1,168 | +0,50 % | OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) | ||
JAGUAR HEALTH | 2,235 | -3,25 % | Jaguar Health, Inc.: Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization... ► Artikel lesen | |
ENDO | - | - | Endo, Inc.: Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting | MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared... ► Artikel lesen |